Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Cost-effectiveness of human papillomavirus vaccination in Germany.

Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W.

Cost Eff Resour Alloc. 2017 Sep 4;15:18. doi: 10.1186/s12962-017-0080-9. eCollection 2017.

2.

Does CIN2 Have the Same Aggressive Potential As CIN3? A Secondary Analysis of High-Grade Cytology Recurrence in Women Treated with Cold-Coagulation Cervical Treatment.

Papoutsis D, Underwood M, Parry-Smith W, Panikkar J.

Geburtshilfe Frauenheilkd. 2017 Mar;77(3):284-289. doi: 10.1055/s-0042-119993.

3.

Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.

Bardach AE, Garay OU, Calderón M, Pichón-Riviére A, Augustovski F, Martí SG, Cortiñas P, Gonzalez M, Naranjo LT, Gomez JA, Caporale JE.

BMC Public Health. 2017 Feb 2;17(1):152. doi: 10.1186/s12889-017-4064-7.

4.

Economic Evaluation of Screening Strategies Combined with HPV Vaccination of Preadolescent Girls for the Prevention of Cervical Cancer in Vientiane, Lao PDR.

Chanthavilay P, Reinharz D, Mayxay M, Phongsavan K, Marsden DE, Moore L, White LJ.

PLoS One. 2016 Sep 15;11(9):e0162915. doi: 10.1371/journal.pone.0162915. eCollection 2016.

5.

Spectrum and progression of disease from condyloma to aggressive anogenital squamous cell carcinoma in 3 HIV-positive patients.

Rodriguez O, Kovarik CL.

JAAD Case Rep. 2016 Jan 29;2(1):47-50. doi: 10.1016/j.jdcr.2015.12.003. eCollection 2016 Jan. No abstract available.

6.

Study of 2 years follow-up of referral patients with abnormal Pap smear.

Behnamfar F, Zafarbakhsh A, Allameh TA.

J Res Med Sci. 2015 Dec;20(12):1147-52. doi: 10.4103/1735-1995.172981.

7.

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.

Liu YJ, Zhang Q, Hu SY, Zhao FH.

BMC Cancer. 2016 Feb 26;16:164. doi: 10.1186/s12885-016-2207-3.

8.

Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

Van Effelterre TP, Hogea C, Taylor SM.

Hum Vaccin Immunother. 2016;12(1):8-19. doi: 10.1080/21645515.2015.1054584.

9.

Physiological and pathophysiological roles for phospholipase D.

Nelson RK, Frohman MA.

J Lipid Res. 2015 Dec;56(12):2229-37. doi: 10.1194/jlr.R059220. Epub 2015 Apr 29. Review.

10.

An updated natural history model of cervical cancer: derivation of model parameters.

Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ.

Am J Epidemiol. 2014 Sep 1;180(5):545-55. doi: 10.1093/aje/kwu159. Epub 2014 Jul 31.

11.

Prediction of spontaneous regression of cervical intraepithelial neoplasia lesions grades 2 and 3 by proteomic analysis.

Uleberg KE, Ovestad IT, Munk AC, Brede C, van Diermen B, Gudlaugsson E, Janssen EA, Hjelle A, Baak JP.

Int J Proteomics. 2014;2014:129064. doi: 10.1155/2014/129064. Epub 2014 Jun 15.

12.

Dynamics of high-risk nonvaccine human papillomavirus types after actual vaccination scheme.

Peralta R, Vargas-De-León C, Cabrera A, Miramontes P.

Comput Math Methods Med. 2014;2014:542923. doi: 10.1155/2014/542923. Epub 2014 Apr 3.

13.

HPV 16 Is Related to the Progression of Cervical Intraepithelial Neoplasia Grade 2: A Case Series.

Loffredo D'Ottaviano MG, Discacciati MG, Andreoli MA, Costa MC, Termini L, Rabelo-Santos SH, Villa LL, Zeferino LC.

Obstet Gynecol Int. 2013;2013:328909. doi: 10.1155/2013/328909. Epub 2013 Dec 4.

14.

Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.

Chen AA, Heideman DA, Boon D, Chen Z, Burk RD, De Vuyst H, Gheit T, Snijders PJ, Tommasino M, Franceschi S, Clifford GM.

Virology. 2014 Jan 5;448:356-62. doi: 10.1016/j.virol.2013.10.033. Epub 2013 Nov 12.

15.

Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.

Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW.

PLoS One. 2013 Nov 18;8(11):e80639. doi: 10.1371/journal.pone.0080639. eCollection 2013.

16.

T cell susceptibility to HIV influences outcome of opportunistic infections.

Saharia KK, Koup RA.

Cell. 2013 Oct 24;155(3):505-14. doi: 10.1016/j.cell.2013.09.045. Epub 2013 Oct 24.

17.

Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Jackson CH, Jit M, Sharples LD, De Angelis D.

Med Decis Making. 2015 Feb;35(2):148-61. doi: 10.1177/0272989X13493143. Epub 2013 Jul 25.

18.

HPV knowledge and impact of genital warts on self esteem and sexual life in Colombian patients.

Piñeros M, Hernández-Suárez G, Orjuela L, Vargas JC, Pérez G.

BMC Public Health. 2013 Mar 25;13:272. doi: 10.1186/1471-2458-13-272.

19.

A cervical abnormality risk prediction model: can we use clinical information to predict which patients with ASCUS/LSIL Pap tests will develop CIN 2/3 or AIS?

Charlton BM, Carwile JL, Michels KB, Feldman S.

J Low Genit Tract Dis. 2013 Jul;17(3):242-7. doi: 10.1097/LGT.0b013e3182730fec.

20.

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.

BMC Infect Dis. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75.

Supplemental Content

Support Center